Tarin D
Nuffield Department of Pathology, University of Oxford, John Radcliffe Hospital, Headington, UK.
Ciba Found Symp. 1988;141:149-69. doi: 10.1002/9780470513736.ch9.
We have adopted various approaches to identifying the genes(s) involved in metastasis. The first has been to observe whether introducing a defined activated oncogene (c-Ha-ras 1) into non-neoplastic cells confers not only tumorigenicity but other characteristics of malignancy. A second approach involves transfection of total genomic DNA from highly metastatic into nonmetastatic tumour cells. Thirdly, we are studying whether treatment of weakly metastatic tumour cells with agents known to influence tumour progression and gene expression (e.g. 12-O-tetradecanoylphorbol-13-acetate or 2'-deoxy-5-azacytidine) can affect metastatic capability. It was found that 3T3 fibroblasts which incorporated and expressed the activated rasH oncogene became tumorigenic and capable of lung colonization but not spontaneously metastatic. Additionally, transfection of inert tumour cells with DNA from highly metastatic human and animal cell lines sometimes markedly augmented their spontaneous metastatic capability and their lung colony-forming potential and induced them to form deposits in many extrapulmonary sites. Treatment of some tumour cell lines with azacytidine and 12-O-tetradecanoylphorbol-13-acetate markedly increased their metastatic behaviour after subcutaneous inoculation. Because several cell divisions occurred to produce the subcutaneous tumour before the cells disseminated, we consider the changed phenotype to be heritable and probably caused by alterations in gene expression. These results suggest that components of the metastatic phenotype are heritable and highly conserved in evolution and can be conferred on previously non-metastatic tumour cells by transfer of genomic DNA. In other studies we found that metastasizing tumour cells reach all organs in the body within minutes of entry into the blood but that the distribution of subsequent secondary tumours is neither uniform nor proportional to the numbers of cells retained in each site. The patterns of distribution of metastases tend to be related to the tissue of origin of the primary tumour. This was confirmed in observations on patients with intractable malignant ascites treated with peritoneo-venous shunts. Co-culture of tumour cells with fragments of various organs in vitro supported the conclusion that the normal cells of organs can support or inhibit secondary tumour formation. These observations collectively indicate that metastasis results from acquired abnormalities in gene regulation in tumour cells, but that the resulting abnormal cell behaviour can sometimes be modified or inhibited by local or systemic conditions in the host.
我们采用了多种方法来鉴定参与转移的基因。第一种方法是观察将特定的活化癌基因(c-Ha-ras 1)导入非肿瘤细胞后,是否不仅赋予其致瘤性,还赋予其恶性肿瘤的其他特征。第二种方法是将高转移性肿瘤细胞的全基因组DNA转染到非转移性肿瘤细胞中。第三种方法是研究用已知影响肿瘤进展和基因表达的试剂(如12-O-十四酰佛波醇-13-乙酸酯或2'-脱氧-5-氮杂胞苷)处理低转移性肿瘤细胞是否会影响其转移能力。研究发现,整合并表达活化rasH癌基因的3T3成纤维细胞具有致瘤性,能够在肺部定植,但不会自发转移。此外,用高转移性人类和动物细胞系的DNA转染惰性肿瘤细胞,有时会显著增强其自发转移能力和肺集落形成潜力,并诱导它们在许多肺外部位形成沉积物。用氮杂胞苷和12-O-十四酰佛波醇-13-乙酸酯处理某些肿瘤细胞系后,皮下接种后其转移行为明显增加。由于在细胞扩散之前发生了几次细胞分裂才形成皮下肿瘤,我们认为改变后的表型是可遗传的,可能是由基因表达的改变引起的。这些结果表明,转移表型的成分在进化中是可遗传且高度保守的,并且可以通过基因组DNA的转移赋予先前无转移能力的肿瘤细胞。在其他研究中我们发现,转移的肿瘤细胞在进入血液后的几分钟内就能到达身体的所有器官,但随后继发性肿瘤的分布既不均匀,也与每个部位保留的细胞数量不成比例。转移的分布模式往往与原发性肿瘤的组织来源有关。这在对顽固性恶性腹水患者进行腹腔-静脉分流治疗的观察中得到了证实。肿瘤细胞与各种器官碎片在体外共培养支持了这样的结论,即器官的正常细胞可以支持或抑制继发性肿瘤的形成。这些观察结果共同表明,转移是由肿瘤细胞基因调控中获得性异常导致的,但由此产生的异常细胞行为有时可以被宿主的局部或全身状况所改变或抑制。